JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.22 4.27

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.17

Max

1.26

Põhinäitajad
By Trading Economics
Sissetulek	-16M -13M
Müük	-15M 14M
Kasumimarginaal	-90.037
Töötajad	103
EBITDA	-16M -10M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+241.53% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-40M 454M
Eelmine avamishind	-3.05
Eelmine sulgemishind	1.22

Uudiste sentiment

By Acuity

15%

85%

16 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. veebr 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

6. veebr 2026, 21:40 UTC

Omandamised, ülevõtmised, äriostud

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6. veebr 2026, 21:22 UTC

Market Talk

Mexico's Inflation Seen Accelerating in January -- Market Talk

6. veebr 2026, 21:17 UTC

Tulu

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6. veebr 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. veebr 2026, 21:14 UTC

Omandamised, ülevõtmised, äriostud

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6. veebr 2026, 21:13 UTC

Tulu

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6. veebr 2026, 21:13 UTC

Tulu

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6. veebr 2026, 21:04 UTC

Market Talk

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6. veebr 2026, 20:34 UTC

Tulu

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

6. veebr 2026, 20:27 UTC

Tulu

These Stocks Are Today's Movers: Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More -- Barrons.com

6. veebr 2026, 20:24 UTC

Market Talk

Oil Futures Settle Higher As U.S.-Iran Talks Get Under Way -- Market Talk

6. veebr 2026, 20:20 UTC

Market Talk

U.S. Natural Gas Futures Retreat Ahead of Weekend -- Market Talk

6. veebr 2026, 19:48 UTC

Tulu

Take-Two, Mondelez Get Analyst Attention -- Barrons.com

6. veebr 2026, 19:30 UTC

Omandamised, ülevõtmised, äriostud

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- WSJ

6. veebr 2026, 19:30 UTC

Omandamised, ülevõtmised, äriostud

Justice Department Asking Industry How Netflix or Paramount Deal for Warner Bros. Might Impact Competition, According to Subpoena -- WSJ

6. veebr 2026, 19:30 UTC

Omandamised, ülevõtmised, äriostud

DOJ Asking if Netflix Engaged in 'Exclusionary Conduct' That May Lead to Monopoly, According to Subpoena -- WSJ

6. veebr 2026, 19:17 UTC

Market Talk

USDA Says Farm Income to Decrease in 2026 -- Market Talk

6. veebr 2026, 18:50 UTC

Tulu

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6. veebr 2026, 18:47 UTC

Market Talk

Natural Gas-Infrastructure Operators Take 'Flight to Scale' -- Market Talk

6. veebr 2026, 18:34 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 412 -- Market Talk

6. veebr 2026, 17:58 UTC

Tulu

Reddit Stock Falls After Strong Earnings. Wall Street Is Debating What's Next. -- Barrons.com

6. veebr 2026, 17:52 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

6. veebr 2026, 17:52 UTC

Market Talk

Tulu

Amazon's CapEx Seen as Misunderstood by Investors -- Market Talk

6. veebr 2026, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

6. veebr 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

6. veebr 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. veebr 2026, 17:18 UTC

Market Talk

Canada's Bizarre Jobs Report Points to Growing Labor Slack -- Market Talk

6. veebr 2026, 17:09 UTC

Market Talk

Dollar on Path to Snap Weekly Losing Streak -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

241.53% tõus

12 kuu keskmine prognoos

Keskmine 4.03 USD 241.53%

Kõrge 6 USD

Madal 2.1 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

16 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.